Lexaria Bioscience Corp. (LEXX)
NASDAQ: LEXX · Real-Time Price · USD
0.882
-0.068 (-7.15%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Lexaria Bioscience Revenue
Lexaria Bioscience had revenue of $20.00K in the quarter ending February 28, 2026, a decrease of -88.51%. This brings the company's revenue in the last twelve months to $368.00K, down -30.03% year-over-year. In the fiscal year ending August 31, 2025, Lexaria Bioscience had annual revenue of $705.92K with 52.05% growth.
Revenue (ttm)
$368.00K
Revenue Growth
-30.03%
P/S Ratio
59.44
Revenue / Employee
$52,571
Employees
7
Market Cap
21.87M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Aug 31, 2025 | 705.92K | 241.65K | 52.05% |
| Aug 31, 2024 | 464.28K | 238.07K | 105.24% |
| Aug 31, 2023 | 226.21K | -29.19K | -11.43% |
| Aug 31, 2022 | 255.40K | -467.34K | -64.66% |
| Aug 31, 2021 | 722.74K | 407.95K | 129.59% |
| Aug 31, 2020 | Pro | Pro | Pro |
| Aug 31, 2019 | Pro | Pro | Pro |
| Aug 31, 2018 | Pro | Pro | Pro |
| Aug 31, 2017 | Pro | Pro | Pro |
| Aug 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Curis | 9.44M |
| Marker Therapeutics | 3.55M |
| OSR Holdings | 2.91M |
| Vistagen Therapeutics | 789.00K |
| VYNE Therapeutics | 570.00K |
| Exicure | 500.00K |
| Serina Therapeutics | 130.00K |
LEXX News
- 5 days ago - Lexaria Launches New Study to Examine Next-Generation GLP-1 Drugs - TheNewswire
- 7 days ago - Lexaria Expects Oral GLP-1 Pills to Generate Billions in New Industry Sales - Accesswire
- 13 days ago - Lexaria's New Animal Study Aims to Expand Valuable Intellectual Property - TheNewswire
- 21 days ago - Lexaria Applauds Eli Lilly's Foundayo(TM) Drug Approval - TheNewswire
- 27 days ago - Lexaria to Begin New Human Clinical Study in GLP-1 - TheNewswire
- 4 weeks ago - Lexaria's Robust Patent Portfolio Continues to Grow - Accesswire
- 5 weeks ago - Lexaria's Oral GLP-1 Drug Strategy Validated by Industry - TheNewswire
- 7 weeks ago - Lexaria Announces New R&D Plans for 2026 - Accesswire